Drug Discovery Today ( IF 7.4 ) Pub Date : 2020-11-04 , DOI: 10.1016/j.drudis.2020.10.029 Samridhi Lal 1 , Timothy J Snape 2
Central nervous system (CNS) cancers are among the most aggressive and devastating. Further, due to unavailability of neuro-oncologists and neurosurgeons, the specialized treatment options of CNS cancers are still not completely available in most parts of the world. Among various strategies of inducing death in cancer cells, inhibition of poly(ADP-ribose) polymerase (PARP) has emerged as a beneficial therapy when combined with other anticancer agents. In this review, we provide a detailed therapeutic update of PARP inhibitors that have shown clinical activity against glioma.
中文翻译:
PARP 抑制剂的治疗更新:对胶质瘤治疗的影响
中枢神经系统 (CNS) 癌症是最具侵袭性和破坏性的癌症之一。此外,由于神经肿瘤学家和神经外科医生的缺席,中枢神经系统癌症的专业治疗方案在世界大部分地区仍未完全可用。在诱导癌细胞死亡的各种策略中,抑制聚(ADP-核糖)聚合酶 (PARP) 在与其他抗癌药物联合使用时已成为一种有益的治疗方法。在这篇综述中,我们提供了 PARP 抑制剂的详细治疗更新,这些抑制剂已显示出针对神经胶质瘤的临床活性。